

Supplementary Tables for “Assessing lung cancer progression and survival with infrared spectroscopy of blood serum”

Additional file 1: Tables S1–S5. These additional tables contain further details on the cohorts of study participants described in Table 1. Table S1 gives details on laboratory parameters. Table S2 lists the number of patients with various comorbidities. Table S3 shows the breakdown of the cohort in terms of three classes (T - tumor size, N - regional lymph node involvement, M - metastasis) used in the definition of patient stages following the TNM Classification of Malignant Tumors. Table S4 displays the p-values for comparing survival functions related to different TNM tumor stages using log-rank testing. Finally, table S5 shows the characteristics of the lung cancer cohort used in the analysis related to the results shown in Figure 4 (a) and (b) in the main text.

	Censored	Non-censored
Leukocytes (#/nL)	8.2 ± 2.18	9.65 ± 3.18
Thrombocytes (#/nL)	277.13 ± 72.76	317.08 ± 95.48
Hemoglobin (g/dL)	13.99 ± 1.71	13.73 ± 1.42
Creatinine (mg/dL)	0.92 ± 0.29	0.94 ± 0.28
GFR (mL/min)	77.43 ± 17.55	76.34 ± 19.29
GPT (U/L)	27.02 ± 9.91	27.08 ± 14.51
GOT (U/L)	25.3 ± 23.36	24.16 ± 15.93
LDH (U/L)	211.22 ± 75.89	235.93 ± 96.55
Cholesterol (mg/dL)	195.24 ± 35.99	197.07 ± 43.45
Albumin (g/dL)	3.76 ± 0.36	3.52 ± 0.49
Cyfra 21-1 (ng/mL)	4.69 ± 11.29	8.19 ± 12.99
NSE (ng/mL)	18.03 ± 5.08	23.35 ± 15.19

Table S1: Distributions of laboratory parameters between censored and non-censored lung-cancer patients, included in the lung-cancer cohort, studied in the survival analysis.

		Censored	Non-censored
Diabetes	Yes	17	16
	No	66	60
	N/A	1	0
High blood pressure	Yes	45	45
	No	36	31
	N/A	3	0
Heart disease	Yes	22	25
	No	59	50
	N/A	3	1
Kidney disease	Yes	5	5
	No	79	71
	N/A	0	0
Rheumatic disease	Yes	2	5
	No	81	70
	N/A	1	1
Fibrosis	Yes	0	0
	No	26	36
	N/A	58	38
Asthma	Yes	2	5
	No	25	33
	N/A	57	38
COPD	Yes	25	31
	No	2	7
	N/A	57	38
COPD grade	GOLD 1	2	8
	GOLD 2	13	14
	GOLD 3	8	5
	GOLD 4	1	2
	N/A	60	47

Table S2: Breakdown of the lung-cancer cohort, studied in the survival analysis, in terms of comorbidities.

		Censored	Non-censored
Class T	T1	30	15
	T2	27	21
	T3	13	10
	T4	13	25
	N/A	1	5
Class N	N0	57	26
	N1	11	6
	N2	6	21
	N3	9	17
	N/A	1	6
Class M	M0	33	31
	M1	9	28
	N/A	42	17

Table S3: Breakdown of the lung-cancer cohort, studied in the survival analysis, in terms of TNM classes.

Compared stages:	I / II	I / III	I / IV	II / III	II / IV	III / IV
p-value:	0.53	0.11	0.005	0.09	0.01	0.05

Table S4: P-values for comparing survival functions related to different TNM tumor stages using log-rank testing

years to event	# patients	Age (years)	% Female
1	33	69 $\pm$ 10	33
2	23	71 $\pm$ 11	48
3	18	68 $\pm$ 12	50
censored	84	68 $\pm$ 9	46

years to event	Stage I	Stage II	Stage III	Stage IV	N/A
1	1	2	8	18	4
2	2	0	6	7	8
3	2	0	4	3	9
censored	11	7	13	9	44

Table S5: Characteristics of the lung cancer cohort used in the analysis related to the results presented in Figure 4 (a) and (b). The first part shows the breakdown of lung cancer patients in terms of demographics. The second part shows tumor staging information according to the TNM Classification of Malignant Tumors (Union for International Cancer Control (UICC)).